Join a Funders Delegation to USSF 2010
February 11, 2010
Inspired by the World Social Forum process, the US Social Forum is a unique space within which grassroots networks are building a powerful multi-racial, multi-sectoral, inter-generational, diverse, inclusive, internationalist movement, seeking solutions to the economic and ecological crises that confront us. The forum is not a conference but rather a remarkable event within an extraordinary process of building political consciousness for a progressive way forward. Funders concerned with issues as diverse as human rights, equity, the environment, poverty, community development, economic justice, immigration and social movement organizing are invited to participate in our delegation to this important gathering.
Defending Mother Earth in Cochabamba
February 1, 2010
A report from Porto Alegre on the Bolivian climate change initiative
CAFTA Restricts Access to Medicines
August 25, 2009 – Ellen Shaffer, Joe Brenner, Health Affairs
Millions of people lack access to affordable medicines. The intellectual property rules in the Central America Free Trade Agreement (CAFTA) provide pharmaceutical companies with monopoly protections that allow them to market some drugs without competition by less costly generics. We examined availability of certain drugs in Guatemala and found that CAFTA intellectual property rules reduced access to some generic drugs already on the market and delayed new entry of other generics. Some drugs protected from competition in Guatemala will become open for generic competition in the United States before generic versions will be legally available in Guatemala. [Health Affairs 28, no. 5 (2009): w957–w968 (published online 25 August 2009; 10.1377/hlthaff.28.5.w957)]
This Is What Denial Does
October 14, 2008 – George Monbiot, The Guardian
The economic crisis is petty by comparison to the nature crunch. But they have the same cause.
Brazil Takes Steps To Import Cheaper AIDS Drug Under Trade Law
May 7, 2007 – Tove Iren S. Gerhardsen, IP Watch
The government of Brazil has issued a license that will allow the importation of cheaper versions of a patented HIV/AIDS drug after negotiations failed to bring about agreement on price reductions with Merck, the US company holding the patent. Merck said it was “profoundly disappointed,” as Brazil’s action sparked a flurry of positive and negative reactions. This is the first compulsory license issued in Brazil after several threats to do so since 2001 resulted in lower prices for other drugs, sources said.